Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
REDX.L Share News (REDX)
REDX Share
Price
REDX Share
News
REDX Share
Chat
REDX Share
Trades
REDX
Live RNS
REDX Share
Charts
REDX Broker
Ratings
REDX Directors
Deals
REDX Financial
Diary
REDX
Fundamentals
REDX Short
Positions
REDX
Media
REDX Company
Research
REDX Company
Timeline
- There is currently no data for REDX
Redx Pharma Identifies Second Drug Development Candidate
LONDON (Alliance News) - Redx Pharma PLC said Tuesday that it has identified a second drug development candidate, a potential new treatment for blood cancers and autoimmune diseases.
The candidate works by inhibiting an enzyme that plays a key role in the development of these illnesses, Bruton's tyrosine kinase.
Redx currently has 13 drug programmes in its pipeline, five of which have achieved pre-clinical proof of concept.
"We're delighted to be announcing the second drug candidate to make it through our development pipeline, particularly one which has the potential to play a role in tackling some challenging blood cancers like leukaemia and diseases of the autoimmune system including rheumatoid arthritis and lupus," said Chief Executive Officer Neil Murray in a statement.
Shares in Redx are trading up 1.6% at 89.90 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest REDX News
- IN BRIEF: Redx Pharma shareholders approve AIM delisting plans
19 Apr 2024 - Director dealings: Redx Pharma CEO ups stake
12 Apr 2024 - LONDON MARKET CLOSE: Europe down after Easter holiday weekend
2 Apr 2024 - Redx Pharma plummets on plans to delist from AIM
2 Apr 2024 - LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth
2 Apr 2024 - AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist
2 Apr 2024 - IN BRIEF: Redx Pharma clarifies not currently pursuing US listing
14 Feb 2024 - Redx Pharma shares skyrocket on deal to sell inhibitor program
7 Feb 2024
Related News
IN BRIEF: Redx Pharma shareholders approve AIM delisting plans
Redx Pharma PLC - clinical-stage biotechnology company - Shareholders pass resolution by 99.75% margin at general meeting to approve cancelling shares...
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stag...
LONDON MARKET CLOSE: Europe down after Easter holiday weekend
(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.
REDX.L News
IN BRIEF: Redx Pharma shareholders approve AIM delisting plans
Redx Pharma PLC - clinical-stage biotechnology company - Shareholders pass resolution by 99.75% margin at general meeting to approve cancelling shares...
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stag...
LONDON MARKET CLOSE: Europe down after Easter holiday weekend
(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.
Redx Pharma plummets on plans to delist from AIM
(Alliance News) - Redx Pharma PLC shares fell on Tuesday, after it said it intends to cancel its shares from trading on AIM in London.
LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth
(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data ac...
AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
IN BRIEF: Redx Pharma clarifies not currently pursuing US listing
Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Responds to a Times article published on Tuesday saying RedX is l...
Redx Pharma shares skyrocket on deal to sell inhibitor program
(Alliance News) - Redx Pharma PLC on Wednesday said it has struck a deal to sell Kirsten rat sarcoma virus inhibitor program to Dublin-based Jazz Phar...
Follow the stocks
